Literature DB >> 18317568

High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD).

Annette Bruchfeld1, Abdul Rashid Qureshi, Bengt Lindholm, Peter Barany, Lihong Yang, Peter Stenvinkel, Kevin J Tracey.   

Abstract

Chronic kidney disease (CKD) is associated with inflammation and malnutrition and carries a markedly increased risk of cardiovascular disease (CVD). High Mobility Group Box Protein-1 (HMGB-1) is a 30-kDa nuclear and cytosolic protein known as a transcription and growth factor, recently identified as a proinflammatory mediator of tissue injury. Recent data implicates HMGB-1 in endotoxin lethality, rheumatoid arthritis, and atherosclerosis. The aim of this post-hoc, cross-sectional study was to determine whether HMGB-1 serum levels are elevated in CKD patients. The study groups were categorized as follows: 110 patients starting dialysis defined as CKD 5; 67 patients with moderately to severely reduced renal function or CKD 3-4; and 48 healthy controls. High-sensitivity C-reactive-protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor (TNF), serum-albumin (S-albumin), hemoglobin A(1c) (HbA(1c)), hemoglobin, subjective global nutritional assessment (SGA), and glomerular filtration rate (GFR) were analyzed. Kruskal-Wallis test was used to compare groups and Spearman's rank correlation test was used for continuous variables. HMGB-1, measured by Western blot, was significantly (P < 0.001) elevated in CKD 5 (146.7 +/- 58.6 ng/mL) and CKD 3-4 (85.6 +/- 31.8) compared with controls (10.9 +/- 10.5). HMGB-1 levels were correlated positively with TNF (Rho = 0.52; P < 0.001), hs-CRP (Rho = 0.38; P < 0.001), IL-6 (Rho = 0.30; P < 0.001), HbA(1c) (Rho = 0.14; P = 0.02) and SGA (Rho = 0.21; P = 0.002) and negatively correlated with GFR (Rho = -0.69; P = 0.0001), Hb (Rho = -0.60; P < 0.001), S-albumin (Rho = -0.31; P < 0.001). The current study has revealed that HMGB-1 is elevated significantly in CKD patients and correlates with GFR as well as markers of inflammation and malnutrition. Future studies may delineate whether HMGB-1 is also a marker of disease activity and severity as well as a predictor of outcome in CKD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18317568      PMCID: PMC2258159          DOI: 10.2119/2007-00107.Bruchfeld

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  35 in total

1.  Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity.

Authors:  R Kokkola; J Li; E Sundberg; A-C Aveberger; K Palmblad; H Yang; K J Tracey; U Andersson; H Erlandsson Harris
Journal:  Arthritis Rheum       Date:  2003-07

2.  High mobility group 1 B-box mediates activation of human endothelium.

Authors:  C J Treutiger; G E Mullins; A-S M Johansson; A Rouhiainen; H M E Rauvala; H Erlandsson-Harris; U Andersson; H Yang; K J Tracey; J Andersson; J E W Palmblad
Journal:  J Intern Med       Date:  2003-10       Impact factor: 8.989

3.  Associations between circulating inflammatory markers and residual renal function in CRF patients.

Authors:  Roberto Pecoits-Filho; Olof Heimbürger; Peter Bárány; Mohamed Suliman; Ingela Fehrman-Ekholm; Bengt Lindholm; Peter Stenvinkel
Journal:  Am J Kidney Dis       Date:  2003-06       Impact factor: 8.860

4.  Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis.

Authors:  Richard S Goldstein; Annette Bruchfeld; Lihong Yang; Abdul R Qureshi; Margot Gallowitsch-Puerta; Nirav B Patel; Brett J Huston; Sangeeta Chavan; Mauricio Rosas-Ballina; Peter K Gregersen; Christopher J Czura; Richard P Sloan; Andrew E Sama; Kevin J Tracey
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

Review 5.  Extracellular role of HMGB1 in inflammation and sepsis.

Authors:  H Wang; H Yang; K J Tracey
Journal:  J Intern Med       Date:  2004-03       Impact factor: 8.989

6.  Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study.

Authors:  Martin J Landray; David C Wheeler; Gregory Y H Lip; David J Newman; Andrew D Blann; Fiona J McGlynn; Simon Ball; John N Townend; Colin Baigent
Journal:  Am J Kidney Dis       Date:  2004-02       Impact factor: 8.860

7.  Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients.

Authors:  Vincenzo Panichi; Umberto Maggiore; Daniele Taccola; Massimiliano Migliori; Giovanni Manca Rizza; Cristina Consani; Alessio Bertini; Stefano Sposini; Rafael Perez-Garcia; Paolo Rindi; Roberto Palla; Ciro Tetta
Journal:  Nephrol Dial Transplant       Date:  2004-02-19       Impact factor: 5.992

8.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation.

Authors:  Paola Scaffidi; Tom Misteli; Marco E Bianchi
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

9.  Reversing established sepsis with antagonists of endogenous high-mobility group box 1.

Authors:  Huan Yang; Mahendar Ochani; Jianhua Li; Xiaoling Qiang; Mahira Tanovic; Helena E Harris; Srinivas M Susarla; Luis Ulloa; Hong Wang; Robert DiRaimo; Christopher J Czura; Haichao Wang; Jesse Roth; H Shaw Warren; Mitchell P Fink; Matthew J Fenton; Ulf Andersson; Kevin J Tracey
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-26       Impact factor: 11.205

10.  High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes.

Authors:  U Andersson; H Wang; K Palmblad; A C Aveberger; O Bloom; H Erlandsson-Harris; A Janson; R Kokkola; M Zhang; H Yang; K J Tracey
Journal:  J Exp Med       Date:  2000-08-21       Impact factor: 14.307

View more
  36 in total

1.  High-mobility group box-1 protein promotes granulomatous nephritis in adenine-induced nephropathy.

Authors:  Yoko Oyama; Teruto Hashiguchi; Noboru Taniguchi; Salunya Tancharoen; Tomonori Uchimura; Kamal K Biswas; Ko-Ichi Kawahara; Takao Nitanda; Yoshihisa Umekita; Martin Lotz; Ikuro Maruyama
Journal:  Lab Invest       Date:  2010-03-15       Impact factor: 5.662

2.  Chronic kidney disease worsens sepsis and sepsis-induced acute kidney injury by releasing High Mobility Group Box Protein-1.

Authors:  Asada Leelahavanichkul; Yuning Huang; Xuzhen Hu; Hua Zhou; Takayuki Tsuji; Richard Chen; Jeffrey B Kopp; Jürgen Schnermann; Peter S T Yuen; Robert A Star
Journal:  Kidney Int       Date:  2011-08-10       Impact factor: 10.612

3.  Post-Injury Administration of Galantamine Reduces Traumatic Brain Injury Pathology and Improves Outcome.

Authors:  Jing Zhao; Michael J Hylin; Nobuhide Kobori; Kimberly N Hood; Anthony N Moore; Pramod K Dash
Journal:  J Neurotrauma       Date:  2017-12-18       Impact factor: 5.269

4.  High-mobility group box 1 inhibits HCO3- absorption in the medullary thick ascending limb through RAGE-Rho-ROCK-mediated inhibition of basolateral Na+/H+ exchange.

Authors:  Bruns A Watts; Thampi George; Andrew Badalamenti; David W Good
Journal:  Am J Physiol Renal Physiol       Date:  2016-06-29

Review 5.  Proteomic biomarkers in kidney disease: issues in development and implementation.

Authors:  Harald Mischak; Christian Delles; Antonia Vlahou; Raymond Vanholder
Journal:  Nat Rev Nephrol       Date:  2015-02-03       Impact factor: 28.314

Review 6.  The role of necrotic cell death in the pathogenesis of immune mediated nephropathies.

Authors:  Neelakshi R Jog; Roberto Caricchio
Journal:  Clin Immunol       Date:  2014-05-17       Impact factor: 3.969

7.  High mobility group box protein-1 correlates with microinflammatory state and nutritional status in continuous ambulatory peritoneal dialysis patients.

Authors:  Nan Zhu; Weijie Yuan; Yi Zhou; Jun Liu; Jinfang Bao; Jing Hao; Wen Miao
Journal:  J Artif Organs       Date:  2011-03-26       Impact factor: 1.731

8.  High-mobility group box 1 in multiple sclerosis.

Authors:  Zohara Sternberg; Daniel Sternberg; Trevor Chichelli; Allison Drake; Neel Patel; Chana Kolb; Kailash Chadha; Jinhee Yu; David Hojnacki
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

9.  Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity.

Authors:  Ayumi Yoshizaki; Kazuhiro Komura; Yohei Iwata; Fumihide Ogawa; Toshihide Hara; Eiji Muroi; Motoi Takenaka; Kazuhiro Shimizu; Minoru Hasegawa; Manabu Fujimoto; Shinichi Sato
Journal:  J Clin Immunol       Date:  2008-09-30       Impact factor: 8.317

10.  Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation.

Authors:  Annette Bruchfeld; Juan J Carrero; Abdul R Qureshi; Bengt Lindholm; Peter Barany; Olof Heimburger; Maowen Hu; Xinchun Lin; Peter Stenvinkel; Edmund J Miller
Journal:  Mol Med       Date:  2009-12-08       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.